Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma

被引：32

作者：

Driessen, Christoph ^{[1
]}

Muller, Rouven ^{[2
]}

Novak, Urban ^{[3
]}

Cantoni, Nathan ^{[4
]}

Betticher, Daniel ^{[5
]}

Mach, Nicolas ^{[6
]}

Rufer, Axel ^{[7
]}

Mey, Ulrich ^{[8
]}

Samaras, Panagiotis ^{[9
]}

Ribi, Karin ^{[10
]}

Besse, Lenka ^{[1
]}

Besse, Andrej ^{[1
]}

Berset, Catherine ^{[11
]}

Rondeau, Stephanie ^{[11
]}

Hawle, Hanne ^{[11
]}

Hitz, Felicitas ^{[1
]}

Pabst, Thomas ^{[3
]}

Zander, Thilo ^{[12
]}

机构：

[1] Kantonsspital St Gallen, Dept Oncol & Hematol, Rorschacherstr 95, CH-9007 St Gallen, Switzerland

[2] Univ Hosp Zurich, Dept Hematol & Oncol, Zurich, Switzerland

[3] Univ Spital Bern, Dept Med Oncol, Inselspital, Bern, Switzerland

[4] Kantonsspital Aarau AG, Div Hematol, Aarau, Switzerland

[5] HFR Fribourg, Div Oncol & Hematol, Fribourg, Switzerland

[6] Univ Hosp Geneva, Geneva, Switzerland

[7] Luzerner Kantonsspital, Div Hematol, Luzern, Switzerland

[8] Kantonsspital Graubunden, Chur, Switzerland

[9] Univ Spital Zurich, Zurich, Switzerland

[10] Int Breast Canc Study Grp, Coordinating Ctr, Bern, Switzerland

[11] Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland

[12] Luzerner Kantonsspital, Dept Med Oncol, Luzern, Switzerland

来源：

BLOOD | 2018年 / 132卷 / 19期

关键词：

UNFOLDED PROTEIN RESPONSE; LOW-DOSE DEXAMETHASONE; DARATUMUMAB MONOTHERAPY; POMALIDOMIDE; CELLS; COMBINATION; CARFILZOMIB; RESISTANCE; PHASE-2; STRESS;

D O I：

10.1182/blood-2018-05-851170

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2097 / 2100

页数：4

共 19 条

[1] Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma [J].

Baz, Rachid C. ;

Martin, Thomas G., III ;

Lin, Hui-Yi ;

Zhao, Xiuhua ;

Shain, Kenneth H. ;

Cho, Hearn J. ;

Wolf, Jeffrey L. ;

Mahindra, Anuj ;

Chari, Ajai ;

Sullivan, Daniel M. ;

Nardelli, Lisa A. ;

Lau, Kenneth ;

Alsina, Melissa ;

Jagannath, Sundar .

BLOOD, 2016, 127 (21) :2561-2568

[2] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma [J].

Chari, Ajai ;

Suvannasankha, Attaya ;

Fay, Joseph W. ;

Arnulf, Bertrand ;

Kaufman, Jonathan L. ;

Ifthikharuddin, Jainulabdeen J. ;

Weiss, Brendan M. ;

Krishnan, Amrita ;

Lentzsch, Suzanne ;

Comenzo, Raymond ;

Wang, Jianping ;

Nottage, Kerri ;

Chiu, Christopher ;

Khokhar, Nushmia Z. ;

Ahmadi, Tahamtan ;

Lonial, Sagar .

BLOOD, 2017, 130 (08) :974-981

[3] Proteolysis: from the lysosome to ubiquitin and the proteasome [J].

Ciechanover, A .

NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2005, 6 (01) :79-86

[4] Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma [J].

Dimopoulos, Meletios A. ;

Palumbo, Antonio ;

Corradini, Paolo ;

Cavo, Michele ;

Delforge, Michel ;

Di Raimondo, Francesco ;

Weisel, Katja C. ;

Oriol, Albert ;

Hansson, Markus ;

Vacca, Angelo ;

Jesus Blanchard, Maria ;

Goldschmidt, Hartmut ;

Doyen, Chantal ;

Kaiser, Martin ;

Petrini, Mario ;

Anttila, Pekka ;

Cafro, Anna Maria ;

Raymakers, Reinier ;

San-Miguel, Jesus ;

de Arriba, Felipe ;

Knop, Stefan ;

Roellig, Christoph ;

Ocio, Enrique M. ;

Morgan, Gareth ;

Miller, Neil ;

Simcock, Mathew ;

Peluso, Teresa ;

Herring, Jennifer ;

Sternas, Lars ;

Zaki, Mohamed H. ;

Moreau, Philippe .

BLOOD, 2016, 128 (04) :497-503

[5] Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08) [J].

Driessen, Christoph ;

Kraus, Marianne ;

Joerger, Markus ;

Rosing, Hilde ;

Bader, Jurgen ;

Hitz, Felicitas ;

Berset, Catherine ;

Xyrafas, Alexandros ;

Hawle, Hanne ;

Berthod, Gregoire ;

Overkleeft, Hermann S. ;

Sessa, Christiana ;

Huitema, Alwin ;

Pabst, Thomas ;

von Moos, Roger ;

Hess, Dagmar ;

Mey, Ulrich J. M. .

HAEMATOLOGICA, 2016, 101 (03) :346-355

[6] Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo [J].

Gills, JoellJ. ;

Lo Piccolo, Jaclyn ;

Tsurutani, Junji ;

Shoemaker, Robert H. ;

Best, Carolyn J. M. ;

Abu-Asab, Mones S. ;

Borojerdi, Jennifer ;

Warfel, Noel A. ;

Gardner, Erin R. ;

Danish, Matthew ;

Hollander, M. Christine ;

Kawabata, Shigeru ;

Tsokos, Maria ;

Figga, William D. ;

Steeg, Patricia S. ;

Dennis, Phillip A. .

CLINICAL CANCER RESEARCH, 2007, 13 (17) :5183-5194

[7]

Harousseau JL, 2006, HAEMATOLOGICA, V91, P1498

[8] Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance [J].

Kraus, M. ;

Bader, J. ;

Overkleeft, H. ;

Driessen, C. .

BLOOD CANCER JOURNAL, 2013, 3 :e103-e103

[9] Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study [J].

Kumar, S. K. ;

Dimopoulos, M. A. ;

Kastritis, E. ;

Terpos, E. ;

Nahi, H. ;

Goldschmidt, H. ;

Hillengass, J. ;

Leleu, X. ;

Beksac, M. ;

Alsina, M. ;

Oriol, A. ;

Cavo, M. ;

Ocio, E. M. ;

Mateos, M. V. ;

O'Donnell, E. K. ;

Vij, R. ;

Lokhorst, H. M. ;

van de Donk, N. W. C. J. ;

Min, C. ;

Mark, T. ;

Turesson, I. ;

Hansson, M. ;

Ludwig, H. ;

Jagannath, S. ;

Delforge, M. ;

Kyriakou, C. ;

Hari, P. ;

Mellqvist, U. ;

Usmani, S. Z. ;

Dytfeld, D. ;

Badros, A. Z. ;

Moreau, P. ;

Kim, K. ;

Otero, P. R. ;

Lee, J. H. ;

Shustik, C. ;

Waller, D. ;

Chng, W. J. ;

Ozaki, S. ;

Lee, J-J ;

de la Rubia, J. ;

Eom, H. S. ;

Rosinol, L. ;

Lahuerta, J. J. ;

Sureda, A. ;

Kim, J. S. ;

Durie, B. G. M. .

LEUKEMIA, 2017, 31 (11) :2443-2448

[10] Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma [J].

Leung-Hagesteijn, Chungyee ;

Erdmann, Natalie ;

Cheung, Grace ;

Keats, Jonathan J. ;

Stewart, A. Keith ;

Reece, Donna E. ;

Chung, Kim Chan ;

Tiedemann, Rodger E. .

CANCER CELL, 2013, 24 (03) :289-304

← 1 2 →